All In Biotech

Drug Trial Radar · NCT07889505

A Phase 2 Two-Part Study of Oral PS1 in Healthy Volunteers and Adults With Newly Diagnosed Type 1 Diabetes

A Phase 2, Two-Part Study of Oral PS1 Comprising a Pharmacokinetic, Safety, and Tolerability Bridging Study in Healthy Volunteers and an Exploratory Efficacy, Safety, Tolerability, and Pharmacokinetic Study in Adults With Newly Diagnosed Type 1 Diabetes

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

36

Planned (sponsor's estimate)

Start

Nov 21, 2026

Primary completion

Aug 15, 2028

Study completion Oct 31, 2028

Sponsor

Lead sponsor
Pharmasaga Co. Ltd.Industry
Sponsor type
Industry
First posted
Oct 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study consists of 2 sub-studies, including Part A and Part B. Part A is intended to further characterize the pharmacokinetic (PK) profile of PS1 based on existing single ascending dose (SAD) and multiple ascending dose (MAD) data, while Part B is designed as an exploratory study to evaluate the potential clinical effects of PS1 in adults with newly diagnosed type 1 diabetes mellitus (T1DM). PS1 is a potential blood glucose-lowering medication being developed by Pharmasaga Co., Ltd. for the treatment of T1DM.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • PS1Drug

    PS1 will be provided as a 120 mg tablet with 25 mg active pharmaceutical ingredient.

  • PlaceboDrug

    Placebo will be provided as a 120 mg tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part B: Change from Baseline in 4-Hour Mixed-Meal Tolerance Test (MMTT)-Stimulated C-Peptide Area Under the Curve (AUC)Time frame: Part B: Approximately 4 months.
  2. Part A: Pharmacokinetics (PK) of PS1Time frame: Day 1-2: predose, and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours after dosing & Day 8.
  3. Part A: Pharmacokinetics (PK) of PS1Time frame: Day 1-2: predose, and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours after dosing & Day 8.
  4. Part A: Pharmacokinetics (PK) of PS1Time frame: Day 1-2: predose, and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours after dosing & Day 8.
  5. Part A: Pharmacokinetics (PK) of PS1Time frame: Day 1-2: predose, and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours after dosing & Day 8.
  6. Part A: Pharmacokinetics (PK) of PS1Time frame: Day 1-2: predose, and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours after dosing & Day 8.
  7. Part A: Pharmacokinetics (PK) of PS1Time frame: Day 1-2: predose, and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours after dosing & Day 8.
  8. Part A: Pharmacokinetics (PK) of PS1Time frame: Day 1-2: predose, and 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours after dosing & Day 8.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.